ArticleJournal of nanobiotechnology2025
Metabolically hijacked Listeria monocytogenes synergizes STING activation and dual cell death for enhanced antitumor immunotherapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundListeria monocytogenes (LM) holds promise as a microbial vector for cancer immunotherapy, yet its clinical translation requires precise engineering to achieve an optimal balance between attenuation and immunogenicity. This study aimed to develop an engineered LM strain that induces metabolic reprogramming while enhancing antitumor efficacy through multimodal immune activation.
resultsWe encapsulated cepharanthine nanoparticles (CEP NPs) into a double-gene attenuated LM strain via electroporation, resulting in the induction of metabolic reprogramming and the emergence of a 'zombie-like' phenotypic state (LM
conclusionsThese findings establish metabolic hijacking of bacterial vectors as a paradigm-shifting strategy that integrates direct tumor killing with multimodal immune activation, overcoming key barriers in microbial immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.